SLC5A2 and chronic kidney disease: Diabetes Mellitus patients with comorbid chronic kidney disease (CKD) with a mean age of 73 years who used SGLT2 inhibitors / GLP-1 RA were less at risk of hypoglycemia when compared with sulfonylureas (adjusted HR, 0.30; 95% CI, 0.14-0.65) [64].